TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03978156
Drug: Dronabinol 2.5 MG
Normalized name: dronabinol 2.5 MG
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take dronabinol daily during 2 week dosing period separated by a one week washout period.
Study: NCT03978156
Drug: Microcrystalline cellulose
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take placebo daily during 2 week dosing period separated by a one week washout period.
Study: NCT01064284
Drug: Recombinant FVIII
Normalized name: HUMAN COAGULATION FACTOR VIII (FVIII, ANTIHEMOPHILIC FACTOR, AHF, PROCOAGULANT COMPONENT) WITH DELETED B-DOMAIN (746-1639)-SEQUENCE: SINGLE-CHAIN RECOMBINANT FVIII COMPOSED OF DOMAINS A1-A1-A2-A2 (1-740), THE B-DOMAIN N-AND C-TERMINAL FRAGMENTS (741-745)
DrugBank: Omfiloctocog alfa (DB19229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
Study: NCT00378287
Drug: rabeprazole sodium
Normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02677051
Drug: Sulforaphane
Normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulforaphane (1-isothiocyanato-4R- (methylsulfinyl)butane) is an isothiocyanate derived from the action of the plant enzyme myrosinase on glucosinolates including glucoraphanin and comes from consumption of many cruciferous vegetables.
Study: NCT03192332
Drug: Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)
DrugBank: Plasminogen (DB16701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
Study: NCT03657407
Drug: Belladonna Opium
Normalized name: belladonna alkaloids / opium
DrugBank: Opium (DB11130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belladonna Opium 16.2-60mg rectal suppository
Study: NCT03657407
Drug: Glycerin Suppository
Normalized name: Leader Pediatric Glycerin Suppository
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerine rectal suppository
Study: NCT00694928
Drug: butoconazole nitrate
Normalized name: Butoconazole Nitrate
DrugBank: Butoconazole (DB00639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: semi-solid, single dose
Study: NCT01670149
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT04150757
Drug: Intranasal ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with vaso-occlusive episode and sickle cell disease in moderate to severe pain determined at triage will receive intranasal ketamine while awaiting IV placement.
Study: NCT03568058
Drug: personalized vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
Study: NCT03568058
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
Study: NCT00231465
Drug: docetaxel (Taxotere®)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.
Study: NCT04380753
Drug: AMG 510
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be enrolled and will receive AMG 510 PO QD.
Study: NCT01260415
Drug: Panitumumab, Oxaliplatin, 5-FU
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Panitumumab 6 mg / kg, given over 60 minutes~* Oxaliplatin 85 mg / m2 combined with leucovorin 400 mg / m2, given over 2 hours OR~* Irinotecan 180 mg / m2 , given over 90 minutes, concurrent with leucovorin 400 mg / m2, given over 90 minutes~* 5FU 400 mg / m2, by bolus infusion~* 5FU 2400 mg / m2, given over 46 hours
Study: NCT01720602
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01720602
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01720602
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01720602
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00902369
Drug: AK106-001616
Normalized name: AK106-001616
DrugBank: AK106-001616 (DB16058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part1: Dose escalation Part2: Dose expansion
Study: NCT00902369
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00250575
Drug: Clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00029900
Drug: ADI PEG
Normalized name: ADI-PEG 20
DrugBank: Pegargiminase (DB06592)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01044693
Drug: Nebivolol 5 mg
Normalized name: nebivolol 5 MG
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebivolol 5mg single oral dose
Study: NCT01044693
Drug: metoprolol tartrate 50 mg
Normalized name: metoprolol tartrate 50 MG
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metoprolol tartrate 50 mg single oral dose
Study: NCT01044693
Drug: Sildenafil25 mg
Normalized name: sildenafil 25 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 25 mg single oral dose
Study: NCT00620802
Drug: CGT-2168
Normalized name: CGT
DrugBank: Cycloguanil (DB14763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (CGT-2168, one capsule each daily)
Study: NCT00620802
Drug: Plavix
Normalized name: Plavix
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: (clopidogrel, 75 mg)
Study: NCT00544687
Drug: CRx-191
Normalized name: CRx-119
DrugBank: CRx-119 (DB05688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical (mometasone furoate + nortriptyline HCl)
Study: NCT00544687
Drug: mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical mometasone furoate
Study: NCT00544687
Drug: nortriptyline HCl
Normalized name: nortriptyline HCl
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical nortriptyline HCl
Study: NCT03765021
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
Study: NCT02285959
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01570907
Drug: Quetiapine Fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg tablet
Study: NCT01977235
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01977235
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01483430
Drug: Ginseol Kg1 (low dose)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 capsule/day (100mg of Ginseol Kg1), Duration: 8 weeks
Study: NCT02714543
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection hyaluronic acid 1500IU once a week for 6 weeks
Study: NCT02714543
Drug: aloevera gel
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: aloevera gel one scoop to be applied 3-4 times daily for 3 months
Study: NCT02425176
Drug: Botulinum toxin A (BoNT-A) 50U
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Drug intervention:~The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.~Drug is only injected once at baseline
Study: NCT02425176
Drug: Botulinum toxin A (BoNT-A) 100U
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
Study: NCT02425176
Drug: Botulinum toxin A (BoNT-A) 200U
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
Study: NCT01483430
Drug: Ginseol Kg1(high dose)
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule/day (300mg of Ginseol Kg1), Duration: 8 weeks
Study: NCT02658422
Drug: Test Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
Study: NCT00400088
Drug: paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.
Study: NCT00400088
Drug: lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
Study: NCT03760666
Drug: Brequinar/Brequinar + Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The first 14 participants had brequinar monotherapy; the final 3 subjects were also exposed to a combination of brequinar + ribavirin.
Study: NCT02658422
Drug: Reference Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water. Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.
Study: NCT01913912
Drug: LDX.
Normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In this study 3 different doses of LDX will be used:~* 30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine~* 50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine~* 70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine
Study: NCT02408770
Drug: ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: selective progesterone receptor modulator
Study: NCT00383851
Drug: ATN-224
Normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00383851
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00563563
Drug: NB32
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
Study: NCT01913912
Drug: sugar pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.
Study: NCT00283985
Drug: Kidrolase
Normalized name: Folate hydrolase G2
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.
Study: NCT00283985
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/ per os at J1, J2 and J4.
Study: NCT00283985
Drug: Erwinase
Normalized name: Erwinase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In case of allergy to Kidrolase~20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles
Study: NCT00088881
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00088881
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02661347
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Study: NCT02596893
Drug: GED-0301
Normalized name: GED-0507-34-Levo
DrugBank: GED-0507-34-Levo (DB16109)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04038008
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 200 mg of fluconazole.
Study: NCT01265147
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg/m2/w
Study: NCT01265147
Drug: Nedaplatin
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/m2/w
Study: NCT00720083
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00720083
Drug: vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00926900
Drug: D-cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg at approximately 1.5 hours prior to cue-exposure training sessions
Study: NCT00962026
Drug: Rilonacept
Normalized name: Rilonacept
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rilonacept given subcutaneously, dose per package labeling, once weekly.
Study: NCT03969875
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 cc
Study: NCT03969875
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 cc of 4mg
Study: NCT01052428
Drug: metoprolol succinate (Toprol XL)
Normalized name: metoprolol succinate Extended Release Oral Tablet [Toprol]
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toprol XL 100 mg once a day for 2 years
Study: NCT01964560
Drug: Lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: oral solution~Concentration: 1 mg/kg - 6 mg/kg BID (2 mg/kg/day - 12 mg/ kg/day)~Route of administration: oral use
Study: NCT01964560
Drug: Lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: tablet~Concentration: 50 mg - 300 mg BID (100 mg/day - 600 mg/day)~Route of administration: oral use
Study: NCT02168439
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02168439
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03912415
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT03912415
Drug: Cisplatin (or Carboplatin)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT03090035
Drug: Pegylated Interferon α2
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-INF was given in a dose of 180 μg/week
Study: NCT03090035
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 \& 3
Study: NCT00866775
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1600 mg QD
Study: NCT00866775
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1200 mg QD
Study: NCT03177070
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As described above. Intravenous injection with visualisation via fluorescence enabled laparoscope.
Study: NCT02595437
Drug: Triferic
Normalized name: Triferic
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01210599
Drug: Pamidronate
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study was a randomized, double blind, dose-escalation trial of IV pamidronate. Study participants were divided among four study phases. Each group received IV placebo or escalating doses of IV pamidronate of 30mg, 60mg, 90mg and 180mg.
Study: NCT02773537
Drug: Femoral nerve catheter and sciatic nerve block
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This nerve block is believed to cause both muscle weakness and numbness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes both the front and the back of the knee to be numb.
Study: NCT02773537
Drug: Adductor canal catheter and selective tibial block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it to control pain. This technique causes both the front and the back of the knee to be numb.
Study: NCT01682603
Drug: Botulinum toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: BoNT-A (BOTOX 300U)
Study: NCT02115243
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04300790
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib (BYL719): starting dose at 300 mg/QD.; 2 tablets once a day, oral administration, continuously during 28-day cycles until disease progression or unacceptable toxicity.
Study: NCT04300790
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg BID with breakfast and dinner. After 3 days, if no (GI) intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days
Study: NCT04300790
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fulvestrant (500 mg IM injections; loading dose 500mg every two weeks for the first month; then every 4 weeks as per standard of care \[SoC\].~Patients should be started on metformin and fulvestrant within 7 to 14 days prior to start on alpelisib (D1C1)
Study: NCT04300790
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 2.5 mg tablets, once daily, orally
Study: NCT04300790
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane 25 mg tablets, once daily, orally
Study: NCT04300790
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin 50 mg tablets, twice daily, orally with breakfast and dinner
Study: NCT04300790
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen 20 mg tablets, once daily, orally
Study: NCT05531344
Drug: Tamsulosin Hydrochloride Capsules
Normalized name: Tamsulosin Hydrochloride Capsules
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applying Tamsulosin Hydrochloride Capsules to treat the patients with Benign Prostatic Hyperplasia
Study: NCT00638391
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03969875
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% bupivacaine
Study: NCT04278885
Drug: Lanadelumab
Normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300mg Lanadelumab s.c. administration every 2 weeks
Study: NCT01366014
Drug: Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: multiple dose, single schedule
Study: NCT00209638
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00209638
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no